pyrroles has been researched along with Hepatocellular Carcinoma in 124 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.23) | 18.7374 |
| 1990's | 5 (4.03) | 18.2507 |
| 2000's | 30 (24.19) | 29.6817 |
| 2010's | 75 (60.48) | 24.3611 |
| 2020's | 10 (8.06) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, W; Shang, L; Wu, W; Zhang, J | 1 |
| Chen, Z; He, Q; Lin, N; Xie, Q; Yan, F; Yang, B; Ye, S; Yuan, T; Zhang, B; Zhu, H | 1 |
| Dautović, E; Halilčević, D; Hatkić, A; Husejnović, MŠ; Rustemović-Čorbić, M; Smajlović, A; Softić, A; Srabović, N | 1 |
| Cong, L; Dong, J; Ke, M; Li, Y; Lv, Y; Wang, X; Zhang, Z; Zhao, S; Zhu, Y | 1 |
| Cheng, W; Fang, S; Gong, YF; Guan, XY; Hu, L; Jiang, LX; Kong, FE; Li, HL; Li, L; Li, MM; Li, Y; Lin, G; Liu, M; Loong, JH; Ma, NF; Ma, S; Mo, JQ; Nam, Y; Ouyang, Q; Sun, Y; Tang, YQ; Wang, JG; Yan, Q; Yang, XD; Yuan, YF; Zhang, Y | 1 |
| Ren, H; Wang, J; Xue, R; Zhou, Y | 1 |
| Chen, J; Han, Y; Lai, J; Shen, Y; Wang, H; Yang, Y; Zhang, L; Zhou, J | 1 |
| Braeuning, A; Lasch, A; Lichtenstein, D; Marx-Stoelting, P | 1 |
| Decaens, T; Lerat, H; Macek Jílková, Z; Marche, PN; Mroweh, M; Roth, G | 1 |
| Gong, C; Huang, J; Liu, Y; Tan, H; Zhang, J; Zhang, Q | 1 |
| Kim, HS; Lahti, S; Ludwig, JM; Sun, L; Xing, M; Zeng, D | 1 |
| Abdjul, DB; Kanno, SI; Namikoshi, M; Yamazaki, H | 1 |
| Chen, XT; Guo, KY; He, YJ; Huang, YX; Li, YH; Song, CY; Wu, BY | 1 |
| Ao, JY; Cai, H; Chai, ZT; Kong, LQ; Ma, DN; Sun, HC; Ye, BG; Zhang, KZ; Zhang, N; Zhang, YY; Zhu, XD | 1 |
| Arai, Y; Arioka, H; Cheng, AL; Chiu, CF; Heo, J; Hidaka, H; Izumi, N; Kudo, M; Lee, YJ; Liang, PC; Morita, S; Park, JH; Park, JW; Sheen, IS | 1 |
| Abdel-Rahman, O | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Jin, Y; Tian, J; Yang, X | 1 |
| Dong, QZ; Gao, XM; Hsu, JL; Hung, MC; Jia, HL; Li, CW; Li, JH; Lim, SO; Lu, L; Luo, Q; Qin, LX; Sheng, YY; Xu, D; Yang, J; Zhang, Y; Zhang, Z; Zhao, Y; Zheng, Y; Zhu, Y | 1 |
| Arai, Y; Aramaki, T; Arioka, H; Furuse, J; Hidaka, H; Ikeda, M; Imanaka, K; Inaba, Y; Izumi, N; Kanazawa, S; Kaneko, S; Kora, S; Kudo, M; Matsui, O; Morita, S; Okusaka, T; Saito, H; Yamashita, T; Yokosuka, O | 1 |
| Barone, C; Basso, M; Biolato, M; Castaldi, P; De Gaetano, AM; Grieco, A; Iaculli, A; Leccisotti, L; Miele, L; Pompili, M; Riccardi, L; Rufini, V | 1 |
| Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Hoh, A; Lieber, J; Vogt, F | 1 |
| de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
| Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Arai, Y; Aramaki, T; Arioka, H; Imanaka, K; Inaba, Y; Kanai, F; Kaneko, S; Kawai, N; Kora, S; Kudo, M; Matsui, O; Nishida, N; Seki, H; Tanaka, T; Yamakado, K; Yamamoto, T | 1 |
| Chang, YC; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL | 1 |
| De Santis, F; Dituri, F; Fabregat, I; Fernando, J; Giannelli, G; Mazzocca, A; Papappicco, P; Paradiso, A; Peidrò, FJ; Sabbà, C | 1 |
| Ancukiewicz, M; Catalano, OA; Duda, DG; Hayano, K; Jain, RK; Jiang, T; Sahani, DV; Zhu, AX | 1 |
| Cheng, AL; Chung, HC; Kang, YK; Kudo, M; Lanzalone, S; Lechuga, MJ; Lin, DY; Omata, M; Park, JW; Pitman Lowenthal, S; Poggi, G; Qin, S; Raymond, E; Song, X; Xu, J; Yang, L | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Cheng, AL; Hsu, C; Lee, BS; Liao, SC; Lin, LI; Liou, JY; Ou, DL | 1 |
| Hayano, K; Sahani, DV; Yoshida, H; Zhu, AX | 1 |
| Davis, MP; Sharma, P; Shinde, SS | 1 |
| Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
| Arioka, H; Asaoka, Y; Ikeda, M; Koike, K; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sakamoto, Y; Shiina, S; Shimizu, S; Tateishi, R; Ueno, H | 1 |
| Chen, KF; Hsu, CY; Huang, JW; Ko, CH; Lin, MW; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH | 1 |
| Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH | 1 |
| Chen, J; Long, Y; Yin, X; Zhou, C | 1 |
| Chen, X; Ding, H; Lan, L; Li, X; Lin, B; Luo, H; Wang, Y; Wu, J; Zhang, H | 1 |
| Bethell, RC; Bond, S; Cianci, J; Draffan, AG; Duan, J; Fraser, BH; Frey, B; Gannon, C; Halim, R; Harding, M; Hufton, R; Jahangiri, S; Jeynes, TP; Kukolj, G; Lilly, M; Lin, B; Luttick, A; Morton, CJ; Nguyen, VT; Pool, B; Porter, K; Pryor, M; Simoneau, B; Tilmanis, D; Tucker, SP; Tyndall, EM; Wirth, V | 1 |
| Chen, KF; Chiang, HC; Chu, PY; Hsu, CY; Huang, JW; Ko, CH; Li, YS; Lin, MW; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH | 1 |
| Cetrangolo, P; Colombo, F; De Santis, F; Maggioni, M; Porretti, L; Prati, D; Razini, P; Torrente, Y; Torresani, E; Trombetta, E | 1 |
| Chang, JH; Chen, KF; Chen, PP; Huang, JW; Shiau, CW; Su, JC; Tseng, PH | 1 |
| Chan, JK; Chung, AY; Endaya, BB; Gnecchi, M; Ho, IA; Hui, KM; Huynh, H; Iyer, NG; Lam, PY; Leong, HS; Lim, KH; Newman, JP; Sia, KC; Toh, XY; Yulyana, Y | 1 |
| Chen, X; Li, W; Shang, SQ; Shen, HQ; Zhao, XL | 1 |
| Asahina, Y; Hara, Y; Hashiba, T; Hayashi, T; Honda, M; Kaneko, S; Kondo, M; Nio, K; Nomura, Y; Oishi, N; Okada, H; Sunagozaka, H; Yamashita, T; Yoshida, M | 1 |
| Kalyan, A; Kulik, L; Nimeiri, H | 1 |
| Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Asha, VV; Sreejith, PS | 1 |
| Hayano, K; Lee, SH; Sahani, DV; Yoshida, H; Zhu, AX | 2 |
| Lin, S; Liu, Z; Wen, T; Wu, G; Yan, W; Yang, W | 1 |
| Ait-Oudhia, S; Fetterly, G; Groman, A; Iyer, R; Mager, DE; Pokuri, V; Tomaszewski, G; Zagst, P | 1 |
| Avella, DM; Cole, DJ; Cooper, TK; Kaifi, JT; Kester, M; Kimchi, ET; Li, G; Li, N; Liu, D; Qi, X; Rockey, DC; Rountree, CB; Schell, TD; Staveley-O'Carroll, KF; Yang, QX | 1 |
| Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
| Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R | 1 |
| Greten, TF; Korangy, F; Malek, NP; Manns, MP | 1 |
| Raymond, E; Zhu, AX | 1 |
| Antonaci, S; Fransvea, E; Giannelli, G; Mazzocca, A | 1 |
| Andresen, CJ; Bagi, CM; Christensen, J; Cohen, DP; Roberts, WG; Swanson, T; Tuthill, T; Wilkie, D | 1 |
| Abrams, TA; Ancukiewicz, M; Bhargava, P; Blaszkowsky, LS; Catalano, OA; Clark, JW; di Tomaso, E; Duda, DG; Enzinger, PC; Fuchs, CS; Hezel, AF; Jain, RK; Kwak, EL; Lahdenranta, J; Meyerhardt, J; Miksad, R; Ryan, DP; Sahani, DV; Sindhwani, V; Yoon, SS; Zhu, AX | 1 |
| Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC | 1 |
| Boucher, E; Cheng, AL; Deprimo, S; Douillard, J; Faivre, S; Harmon, C; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E; Ruiz-Garcia, A; Zappa, M | 1 |
| Bruix, J; Forner, A; Llovet, JM | 1 |
| Antonaci, S; Fransvea, E; Giannelli, G; Lavezzari, G; Mazzocca, A | 1 |
| Chang, AP; Choo, SP; Chow, PK; Chung, AY; Huynh, H; Jin, Y; Koong, HN; Ngo, VC; Ong, HS; Ong, LC; Poon, D; Song, IC; Soo, KC; Thng, CH; Toh, HC; Zheng, L | 1 |
| Antonaci, S; Dituri, F; Fransvea, E; Giannelli, G; Lupo, L; Mazzocca, A | 1 |
| Healy, ME; Krajewski, KM; Lai, KC; Miksad, RA; Rojas, R; Stein, MC; Zhu, AX | 1 |
| Bouattour, M; Dreyer, C; Faivre, SJ; Raymond, E | 1 |
| Wang, ZY | 1 |
| Amann, T; Bataille, F; Bosserhoff, AK; Dettmer, K; Hellerbrand, C; Kiefer, P; Liedtke, C; Mühlbauer, M; Oefner, PJ; Spruss, T; Trautwein, C; Wild, P | 1 |
| Chang, CC; Chi, KH; Ko, HL; Liao, CS; Mehta, MP; Tsang, YW; Yang, KC | 1 |
| Bodoky, G; Borner, M; Hess, V; Inauen, R; Koeberle, D; Kovàcs, K; Lerch, S; Limacher, A; Majno, P; Montemurro, M; Roth, A; Saletti, P; Samaras, P; Simcock, M | 1 |
| Arioka, H; Ikeda, M; Kanai, F; Kawabe, T; Kondo, Y; Morizane, C; Obi, S; Okusaka, T; Omata, M; Sato, S; Shiina, S; Tagawa, K; Taniguchi, M; Tateishi, R; Yoshida, H | 1 |
| Berardi, R; Cascinu, S; Del Prete, M; Di Pietro Paolo, M; Faloppi, L; Maccaroni, E; Scartozzi, M | 1 |
| Ancukiewicz, M; Clark, JW; di Tomaso, E; Duda, DG; Fuchs, CS; Jain, RK; Miksad, R; Ryan, DP; Zhu, AX | 1 |
| Antonaci, S; Azzariti, A; Fransvea, E; Giannelli, G; Mazzocca, A; Santamato, A | 1 |
| Hagymási, K; Tulassay, Z | 1 |
| Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
| Bieche, I; Bouattour, M; Dokmak, S; Faivre, S; Marijon, H; Paradis, V; Raymond, E; Zappa, M | 1 |
| Arzeno, J; Bellovin, DI; Cao, Z; Fan-Minogue, H; Felsher, DW; Gambhir, SS; Yang, Q; Yevtodiyenko, A | 1 |
| Baudelet, C; Finn, RS; Harris, R; Ismail, F; Karwal, M; Kim, JS; Li, RK; Park, JW; Raoul, JL; Thomas, M; Walters, I | 1 |
| Bouattour, M; Boucher, E; Cheng, AL; Dokmak, S; Douillard, JY; Dreyer, C; Faivre, S; Im, SA; Kang, YK; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E; Sablin, MP; Serrate, C; Vilgrain, V; Zappa, M | 1 |
| Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM | 1 |
| Agnelli, L; Baccarin, M; Baldan, F; Bertolini, F; Cadamuro, M; Cattaneo, A; Colombo, F; Foglieni, B; Guerneri, S; Maggioni, M; Marighetti, P; Martin-Padura, I; Mazzaferro, V; Mazzucchelli, S; Porretti, L; Prati, D; Rebulla, P; Rossi, G; Spreafico, M | 1 |
| Boucher, E; Cheng, AL; DePrimo, SE; Douillard, JY; Faivre, S; Harmon, CS; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E | 1 |
| Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC | 1 |
| Avella, DM; Berg, A; Garcia, LS; Isom, HC; Kester, M; Kimchi, ET; Li, G; Liu, D; Lou, X; Rountree, CB; Schell, TD; Shereef, S; Staveley-O'Carroll, KF; Tagaram, HR; Yang, Q; Zhang, SS | 1 |
| Enooku, K; Goto, T; Kanai, F; Koike, K; Kondo, Y; Masuzaki, R; Omata, M; Shiina, S; Tateishi, R; Yoshida, H | 1 |
| Burzynska, B; Gora, M; Hoser, G; Iwanicka-Nowicka, R; Kiliszek, M; Koblowska, M; Kotlinski, M; Leszczynska, A; Plochocka, D; Rawa, K; Szkopinska, A | 1 |
| Choi, MJ; Hong, S; Hong, SS; Hong, SW; Jung, KH; Lee, H; Lee, HS; Zheng, HM | 1 |
| Andresen, CJ; Bagi, CM; Gebhard, DF | 1 |
| Baldassarre, F; Ciccarella, G; De Santis, F; Giannelli, G; Leporatti, S; Lucarelli, G; Rinaldi, R; Scarlino, F; Torre, AD; Vergaro, V | 1 |
| Chen, KC; Chen, KF; Chen, WL; Huang, JW; Liu, CY; Shiau, CW; Su, JC; Tai, WT | 1 |
| Chen, KF; Chen, PJ; Cheng, AL; Lin, JP; Liu, CY; Shiau, CW; Tai, WT; Yu, HC | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Boleti, E; Chowdury, S; Crabb, S; Jones, R; Lim, L; Nathan, P; Powles, T; Protheroe, A; Sarwar, N; Shamash, J; Stockdale, A; Wilson, P | 1 |
| Chang, AY; Wang, M | 1 |
| Frampas, E; Koscielny, S; Lassau, N; Vilgrain, V; Vullierme, MP; Zappa, M | 1 |
| MAN'KO, IV; PETROVA, MF; PUKHAL'SKAIA, ACh | 1 |
| de Maat, MM; de Rooij, BJ; Kleemann, R; Kooistra, T; Lindeman, J; Princen, HM; Szalai, AJ; Verschuren, L | 1 |
| Chen, B; Larsen, SH; Li, CY; Sun, HB; Wang, SY; Xu, WX; Yang, RF; Yang, X; Yue, PB; Zhan, YQ; Zheng, H | 1 |
| Feldmann, G; Halmos, G; Lasfer, M; Nagy, A; Pessayre, D; Reyl-Desmars, FJ; Schally, AV; Vadrot, N | 1 |
| Botma, GJ; Jansen, H; van Deursen, D; van Hoek, M; Verhoeven, AJ; Vieira, D | 1 |
| Guillard, R; Issandou, M; Venteclef, N | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Barzon, L; Castagliuolo, I; Chiarelotto, G; Dalla Via, L; Ferlin, MG; Gasparotto, V; Palù, G; Pezzi, V | 1 |
| Goez, P; Hagelgans, A; Hempel, U; Heyne, B; Jaross, W; Menschikowski, M; Neumeister, V; Siegert, G | 1 |
| Mahendran, R; Pook, SH; Toh, CK | 1 |
| Ho, SS; Pal, S | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D; Sutter, AP | 1 |
| Bernik, MM; Bertolami, MC; Britto, LR; Curi, R; Dorea, EL; Hirata, MH; Hirata, RD; Rebbechi, IM; Rodrigues, AC | 1 |
| Mistafa, O; Roudier, E; Stenius, U | 1 |
| Zhu, AX | 1 |
| Halmos, G; Schally, AV; Seitz, S; Szepeshazi, K; Treszl, A | 1 |
| Draper, CD; Hutson, JL; Inglis, GG; Procopiou, PA; Ross, BC; Watson, NS | 1 |
| Bergstrom, JD; Bostedor, RG; Chao, YS; Geissler, WM; Rew, DJ; Wright, SD | 1 |
| Hirata, H; Inoue, K; Kamata, K; Kano, H; Kuno, K; Seki, T; Takemoto, H; Tsubura, A; Yamamoto, A; Yamamoto, C; Yamamoto, D | 1 |
| Baader, E; Bartmann, W; Beck, G; Bergmann, A; Granzer, E; Jendralla, H; Kesseler, K; Krause, R; Schubert, W; von Kerekjarto, B | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
| Cheng, CC; Zee-Cheng, KY | 1 |
| Schoental, R; Williams, AO | 1 |
| Pitot, HC; Weiss, JW | 1 |
10 review(s) available for pyrroles and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment.
Topics: Aminopyridines; Carcinoma, Hepatocellular; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Liver Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Tumor Microenvironment | 2021 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines | 2015 |
Molecular therapy for the treatment of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Early development of sunitinib in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Indoles; Liver Neoplasms; Pyrroles; Sunitinib | 2009 |
Sunitinib and the benefits of a negative study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Pyrroles; Sunitinib | 2009 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
Some antineoplastic antibiotics.
Topics: Adenocarcinoma; Amino Sugars; Animals; Antibiotics, Antineoplastic; Azaserine; Benzazepines; Bleomycin; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Cricetinae; Dactinomycin; Daunorubicin; DNA; Dogs; Glycosides; Haplorhini; Humans; Leukemia L1210; Liver Neoplasms; Lymphoma; Mice; Mitomycins; Naphthacenes; Plicamycin; Pyrroles; Rats; RNA; Sarcoma 180; Streptonigrin; Streptozocin | 1972 |
20 trial(s) available for pyrroles and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Double-Blind Method; Early Termination of Clinical Trials; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Survival Analysis; Treatment Outcome | 2018 |
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2018 |
A phase II study of sunitinib in advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Humans; Indoles; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxindoles; Propionates; Proportional Hazards Models; Pyrroles; Time Factors; Treatment Outcome | 2013 |
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Sunitinib | 2013 |
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2013 |
Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boston; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fractals; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pyrroles; Radiography; Sunitinib | 2014 |
Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Oxindoles; Oxonic Acid; Propionates; Pyrroles; Tegafur; Treatment Outcome | 2014 |
Dynamic Contrast-Enhanced MRI Kinetic Parameters as Prognostic Biomarkers for Prediction of Survival of Patient with Advanced Hepatocellular Carcinoma: A Pilot Comparative Study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Pyrroles; Sunitinib | 2015 |
Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Humans; Indoles; Liver Neoplasms; Models, Theoretical; Neovascularization, Pathologic; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib | 2009 |
Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome | 2010 |
A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Area Under Curve; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Necrosis; Oxindoles; Propionates; Pyrroles; Survival Analysis; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2011 |
Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Blood Platelets; Carcinoma, Hepatocellular; Cell Count; Cytokines; Female; Hematopoietic Stem Cells; Hemoglobins; Humans; Indoles; Leukocytes; Liver Neoplasms; Male; Middle Aged; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Treatment Outcome | 2011 |
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Pyrroles; Treatment Outcome; Triazines; Tumor Burden | 2011 |
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Perfusion Imaging; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2011 |
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Neoplasm Proteins; Pyrroles; ROC Curve; Sunitinib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor C | 2011 |
Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Precursors; Prothrombin; Pyrroles; Time Factors; Treatment Outcome; Tumor Burden | 2012 |
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prognosis; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2013 |
95 other study(ies) available for pyrroles and Hepatocellular Carcinoma
| Article | Year |
|---|---|
Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells.
Topics: Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Liver Neoplasms; Naphthoquinones; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Pyrroline Carboxylate Reductases; TOR Serine-Threonine Kinases | 2022 |
CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Hypoxia; Liver Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides | 2022 |
Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Fluorobenzenes; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Pyrimidines; Pyrroles; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2023 |
MicroRNA-148b-colony-stimulating factor-1 signaling-induced tumor-associated macrophage infiltration promotes hepatocellular carcinoma metastasis.
Topics: Aminopyridines; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Neoplasms, Experimental; Pyrroles; Signal Transduction | 2019 |
A hepatocyte differentiation model reveals two subtypes of liver cancer with different oncofetal properties and therapeutic targets.
Topics: Aminopyridines; Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Differentiation; Cell Line; Cell Transformation, Neoplastic; Cohort Studies; Disease-Free Survival; E2F1 Transcription Factor; Female; Gene Expression Profiling; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Hepatectomy; Hepatocytes; Human Embryonic Stem Cells; Humans; Hydroxyquinolines; Isoquinolines; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Mice; Middle Aged; Prognosis; Pyridines; Pyrroles; Signal Transduction; Smad3 Protein; Xenograft Model Antitumor Assays | 2020 |
Puerarin inhibits hepatocellular carcinoma invasion and metastasis through miR-21-mediated PTEN/AKT signaling to suppress the epithelial-mesenchymal transition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; Isoflavones; Liver Neoplasms; Male; MicroRNAs; Neoplasm Invasiveness; PTEN Phosphohydrolase; Pyrroles | 2020 |
Phospholipid-Decorated Glycogen Nanoparticles for Stimuli-Responsive Drug Release and Synergetic Chemophotothermal Therapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Drug Liberation; Glycogen; Hemolysis; Humans; Hyperthermia, Induced; Infrared Rays; Liver Neoplasms; Mice, Inbred BALB C; Nanoparticles; Phospholipids; Photochemotherapy; Polymers; Pyrroles | 2020 |
More than additive effects on liver triglyceride accumulation by combinations of steatotic and non-steatotic pesticides in HepaRG cells.
Topics: Adverse Outcome Pathways; Carcinoma, Hepatocellular; Cell Line, Tumor; Dioxolanes; Dioxoles; Fatty Acids; Fatty Liver; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Models, Theoretical; Pesticides; Pyrroles; Triazoles; Triglycerides | 2021 |
Synthesis and evaluation of FAK inhibitors with a 5-fluoro-7H-pyrrolo[2,3-d]pyrimidine scaffold as anti-hepatocellular carcinoma agents.
Topics: Animals; Binding Sites; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Focal Adhesion Protein-Tyrosine Kinases; Half-Life; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Small Molecule Libraries; Structure-Activity Relationship; Transplantation, Heterologous | 2021 |
In vitro biologic efficacy of sunitinib drug-eluting beads on human colorectal and hepatocellular carcinoma-A pilot study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug-Eluting Stents; Humans; In Vitro Techniques; Indoles; Liver Neoplasms; Pyrroles; Sunitinib | 2017 |
A bromopyrrole-containing diterpene alkaloid from the Okinawan marine sponge Agelas nakamurai activates the insulin pathway in Huh-7 human hepatoma cells by inhibiting protein tyrosine phosphatase 1B.
Topics: Agelas; Alkaloids; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Diterpenes; Enzyme Inhibitors; Humans; Insulin; Japan; Liver Neoplasms; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Pyrroles; Signal Transduction | 2017 |
Sunitinib Induces NK-κB-dependent NKG2D Ligand Expression in Nasopharyngeal Carcinoma and Hepatoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Coculture Techniques; Combined Modality Therapy; Cytotoxicity, Immunologic; Gene Expression; Hep G2 Cells; Humans; Immunologic Surveillance; Immunotherapy, Adoptive; Indoles; Killer Cells, Natural; Ligands; Liver Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; NF-kappa B; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Pyrroles; RNA, Small Interfering; Signal Transduction; Sunitinib | 2017 |
Colony-Stimulating Factor 1 Receptor Blockade Inhibits Tumor Growth by Altering the Polarization of Tumor-Associated Macrophages in Hepatocellular Carcinoma.
Topics: Aminopyridines; Animals; Biomarkers, Tumor; Bone Marrow Cells; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Polarity; Cell Proliferation; Humans; Liver Neoplasms; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Biological; Monocytes; Phenotype; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Tumor Microenvironment | 2017 |
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1 | 2018 |
Targeted polypyrrole nanoparticles for the identification and treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Phototherapy; Polymers; Pyrroles; Theranostic Nanomedicine | 2018 |
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotaxis; Cytokines; Gene Deletion; Humans; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice, Knockout; Molecular Targeted Therapy; Osteopontin; Prognosis; Pyrroles; Tumor Cells, Cultured; Tumor Escape; Tumor Microenvironment | 2019 |
Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Humans; Indoles; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxindoles; Propionates; Protein Kinase Inhibitors; Pyrroles; Survival Rate; Treatment Outcome | 2019 |
BH3 mimetics reduce adhesion and migration of hepatoblastoma and hepatocellular carcinoma cells.
Topics: Actins; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase Inhibitors; cdc42 GTP-Binding Protein; Cell Adhesion; Cell Movement; Cytoskeleton; Enzyme Activation; Fluorescent Antibody Technique; Hepatoblastoma; Humans; Indoles; Neoplasm Metastasis; Nitrophenols; Oligopeptides; Piperazines; Proteolysis; Pseudopodia; Pyrroles; Sulfonamides | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 2; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Connective Tissue Growth Factor; Female; Hep G2 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Male; Middle Aged; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Quinolines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Transcription Factors; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2013 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Everolimus; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptors, Somatomedin; Signal Transduction; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Acute hyperammonemic encephalopathy in a non-cirrhotic patient with hepatocellular carcinoma reversed by arginine therapy.
Topics: Antineoplastic Agents; Arginine; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Humans; Hyperammonemia; Indoles; Liver Neoplasms; Male; Pyrroles; Sunitinib; Young Adult | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Proteins; Mice, Nude; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Phagosomes; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; RNA Interference; STAT3 Transcription Factor; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |
Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Combined Modality Therapy; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Propensity Score; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome | 2015 |
Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Flavonoids; Hep G2 Cells; Humans; Liver Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; RNA Interference; Signal Transduction; Smad Proteins; Transfection; Transforming Growth Factor beta | 2014 |
Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Proliferation; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Neoplasms; Molecular Structure; Nucleosides; Pyrroles; RNA, Viral; Structure-Activity Relationship; Triazines; Tumor Cells, Cultured; Virus Replication | 2014 |
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatin Immunoprecipitation; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Giant Lysosomes as a Chemotherapy Resistance Mechanism in Hepatocellular Carcinoma Cells.
Topics: ATP-Binding Cassette Transporters; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Humans; Indoles; Liver Neoplasms; Lysosomes; Pyrroles; Sunitinib | 2014 |
Copper-obatoclax derivative complexes mediate DNA cleavage and exhibit anti-cancer effects in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Copper; DNA Cleavage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Indoles; Liver Neoplasms; Molecular Structure; Organometallic Compounds; Pyrroles; Structure-Activity Relationship | 2015 |
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Culture Media, Conditioned; Fetus; Gene Knockdown Techniques; Humans; Indoles; Liver Neoplasms; Mesenchymal Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib; Sunitinib | 2015 |
Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase 9; Female; Fluorouracil; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Piperidones; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrroles; Xenograft Model Antitumor Assays | 2015 |
TSU-68 ameliorates hepatocellular carcinoma growth by inhibiting microenvironmental platelet-derived growth factor signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Mice; Oxindoles; Platelet-Derived Growth Factor; Propionates; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Transforming Growth Factor beta1 | 2015 |
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1 | 2015 |
Glycopentalone, a novel compound from Glycosmis pentaphylla (Retz.) Correa with potent anti-hepatocellular carcinoma activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Ethanol; Humans; Liver Neoplasms; Mice; Molecular Structure; Plant Extracts; Propane; Pyrroles; Rutaceae | 2015 |
Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Indoles; Kinetics; Liver Circulation; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Pyrroles; Sunitinib | 2015 |
[Reversal of stemness in multidrug-resistant hepatocellular carcinoma cells by SIS3].
Topics: AC133 Antigen; Animals; Antibiotics, Antineoplastic; Antigens, CD; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Doxorubicin; Drug Resistance, Neoplasm; Glycoproteins; Heterografts; Humans; Isoquinolines; Liver Neoplasms; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Peptides; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; Smad3 Protein; Tumor Stem Cell Assay | 2015 |
Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Topics: Adoptive Transfer; Animals; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cytotoxicity, Immunologic; Disease Models, Animal; Enzyme Inhibitors; Histocompatibility Antigens Class II; Immune Tolerance; Immunotherapy; Indoles; Liver Neoplasms; Mice; Neoplasm Staging; Programmed Cell Death 1 Receptor; Pyrroles; Sunitinib; T-Lymphocytes, Regulatory | 2017 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
Topics: Aged; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Extracellular Matrix Proteins; Female; Humans; Integrin alpha5beta1; Integrin beta1; Liver Neoplasms; Male; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1 | 2009 |
Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Models, Animal; Dose-Response Relationship, Drug; Focal Adhesion Kinase 2; Humans; Indoles; Liver Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Nude; Sulfonamides; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemokine CXCL12; Female; Humans; Indoles; Interleukin-6; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Stem Cells; Sunitinib | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult | 2009 |
Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Embryonic Development; Humans; Liver Neoplasms; Neovascularization, Pathologic; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2009 |
Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, SCID; Neovascularization, Pathologic; Phosphorylation; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays | 2009 |
Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Connective Tissue Growth Factor; Disease Progression; Down-Regulation; Humans; Liver Neoplasms; Pyrazoles; Pyrroles; Transforming Growth Factor beta; Tumor Cells, Cultured | 2010 |
Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Gait Disorders, Neurologic; Hepatitis, Autoimmune; Humans; Indoles; Liver Neoplasms; Male; Postural Balance; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sensation Disorders; Sunitinib | 2009 |
Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Endpoint Determination; Humans; Indoles; Liver Neoplasms; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.
Topics: Aged; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Down-Regulation; Female; Fibroblast Growth Factor 7; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pyrroles; Receptor, Fibroblast Growth Factor, Type 2 | 2010 |
Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Gastrointestinal Hemorrhage; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Pyrroles; Radiotherapy, Intensity-Modulated; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome | 2010 |
Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.
Topics: Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Liver; Liver Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2011 |
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome | 2010 |
Epithelial-to-mesenchymal transition and acquired resistance to sunitinib in a patient with hepatocellular carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Indoles; Liver Neoplasms; Male; Pyrroles; Radiography; Sunitinib | 2011 |
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Mice, SCID; Mice, Transgenic; Mutation; Phosphorylation; Proto-Oncogene Proteins c-myc; Pyrroles; rac GTP-Binding Proteins; Serine; Threonine; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2012 |
Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Cell Shape; Clone Cells; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Genome, Human; Humans; Indoles; Liver Neoplasms; Mice; Microscopy, Fluorescence; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrroles; Sunitinib; Time Factors; Tumor Cells, Cultured | 2011 |
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model.
Topics: Adenocarcinoma; Adoptive Transfer; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Disease Models, Animal; Hep G2 Cells; Hepatocytes; Humans; Immune Tolerance; Immunocompetence; Indoles; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; STAT3 Transcription Factor; Sunitinib | 2012 |
Different statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Computational Biology; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Profiling; Gene Expression Regulation; Genome, Human; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Metabolic Networks and Pathways; Mevalonic Acid; Oligonucleotide Array Sequence Analysis; Pilot Projects; Principal Component Analysis; Pyrroles; Simvastatin | 2011 |
HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2012 |
Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Pyrroles; Sunitinib; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2012 |
Polyelectrolyte capsules as carriers for growth factor inhibitor delivery to hepatocellular carcinoma.
Topics: Biocompatible Materials; Capsules; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Cross-Linking Reagents; Drug Carriers; Drug Compounding; Endocytosis; Glutaral; Humans; Liver Neoplasms; Microscopy, Confocal; Microscopy, Electron, Scanning; Polyamines; Polyelectrolytes; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta | 2012 |
A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Indoles; Liver Neoplasms; Mice; Mice, Nude; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; STAT3 Transcription Factor | 2012 |
Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Biomimetic Materials; Carcinoma, Hepatocellular; Down-Regulation; HEK293 Cells; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Oligopeptides; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Thiazoles; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
[Studies on the effect of 6 alkaloids related to 1-methylpyrrolizidine on the growth of hepatoma and of certain other transplanted tumors in animals].
Topics: Alkaloids; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Liver Neoplasms, Experimental; Neoplasm Transplantation; Neoplasms, Experimental; Pyrroles | 1959 |
Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.
Topics: Animals; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cholesterol; Down-Regulation; Gene Expression; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Proteins; In Vitro Techniques; Interleukin-1; Male; Mice; Mice, Transgenic; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Pyrroles; Receptors, Cytoplasmic and Nuclear; Simvastatin; Transcription Factors; Up-Regulation | 2004 |
SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Topics: 3T3 Cells; Animals; Carcinoma, Hepatocellular; Cells, Cultured; DNA; Dose-Response Relationship, Drug; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Gene Expression; Hepatocyte Growth Factor; Hepatocytes; Humans; Indoles; Liver Neoplasms; Mice; Neoplasm Invasiveness; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Pyrroles; Tyrosine | 2004 |
Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.
Topics: Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytotoxins; DNA Primers; Doxorubicin; Humans; Liver Neoplasms; Pyrroles; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Somatostatin | 2005 |
Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression.
Topics: Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; DNA-Binding Proteins; Fatty Acids, Unsaturated; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Homeostasis; Humans; Lipase; Liver Neoplasms; Oleic Acid; Promoter Regions, Genetic; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transcription Factors | 2005 |
The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene: lanosterol cyclase activity.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Primers; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Intramolecular Transferases; Kinetics; Lipid Metabolism; Liver Neoplasms; Oxazoles; Polymerase Chain Reaction; Pyrroles; Rats | 2005 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Synthesis and in vitro and in vivo antitumor activity of 2-phenylpyrroloquinolin-4-ones.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Microtubules; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Pyrroles; Quinolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2005 |
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
Topics: Amides; Aorta; Atorvastatin; Bacterial Proteins; Bacterial Toxins; Butadienes; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Drug Synergism; Flavonoids; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Janus Kinase 2; Lovastatin; Myocytes, Smooth Muscle; NF-kappa B; Nitriles; Phospholipases A; Phospholipases A2; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyridines; Pyrroles; RNA Stability; Up-Regulation | 2005 |
Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity.
Topics: Acetylcysteine; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cell Line, Tumor; Down-Regulation; Drug Antagonism; Drug Screening Assays, Antitumor; Enzyme Activation; Guanidines; Humans; Nasopharyngeal Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Silybin; Silymarin; Sulfhydryl Compounds; Up-Regulation | 2006 |
Margarine phytosterols decrease the secretion of atherogenic lipoproteins from HepG2 liver and Caco2 intestinal cells.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Atherosclerosis; Atorvastatin; Caco-2 Cells; Carcinoma, Hepatocellular; Cholesterol; Drug Synergism; Enterocytes; Hepatocytes; Heptanoic Acids; Humans; Liver Neoplasms; Margarine; Phytosterols; Pyrroles; Sitosterols; Stigmasterol | 2005 |
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Hepatocytes; Humans; Liver Neoplasms; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Messenger | 2006 |
Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Primers; Down-Regulation; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Monocytes; Organic Anion Transporters; Pyrroles; Rhodamine 123; RNA, Messenger | 2006 |
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinoma, Hepatocellular; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Etoposide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Morpholines; Phosphorylation; Pravastatin; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2006 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bombesin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Gonadotropin-Releasing Hormone; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Pyrroles; Radioligand Assay; Receptors, Bombesin; Receptors, LHRH; Receptors, Somatostatin; Transplantation, Heterologous | 2008 |
Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors.
Topics: Carcinoma, Hepatocellular; Cholesterol; Humans; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Lovastatin; Molecular Structure; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cholesterol; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Liver Neoplasms; Male; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Cycloprodigiosin hydrochloride, a new H(+)/Cl(-) symporter, induces apoptosis in human and rat hepatocellular cancer cell lines in vitro and inhibits the growth of hepatocellular carcinoma xenografts in nude mice.
Topics: Animals; Antiporters; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Humans; Hydrogen-Ion Concentration; Indoles; Liver Neoplasms; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Transplantation; Pyrroles; Rats; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids.
Topics: Animals; Anticholesteremic Agents; Carcinoma, Hepatocellular; Chemical Phenomena; Chemistry; Cholesterol; Dogs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lovastatin; Male; Molecular Structure; Pyrroles; Rabbits; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |
Hepatotoxicity of Senecio abyssinicus. Experimental and ultrastructural studies.
Topics: Aflatoxins; Alkaloids; Animals; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Diet; Folklore; Liver; Liver Neoplasms; Male; Microscopy, Electron; Nigeria; Plants, Toxic; Pyrroles; Rats; Senecio; Staining and Labeling | 1970 |
Inhibition of ribosomal RNA maturation in Novikoff hepatoma cells by toyocamycin, tubercidin, and 6-thioguanosine.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Guanosine; Liver Neoplasms; Mercaptopurine; Methionine; Neoplasms, Experimental; Nitriles; Pyrimidines; Pyrroles; Ribonucleosides; RNA, Neoplasm; RNA, Ribosomal; Tritium; Uridine | 1974 |